BRIEF-Resverlogix explores potential of Apabetalone in phase 3 Betonmace clinical study

Tue May 24, 2016 8:18pm EDT
Email This Article |
Share This Article
  • Facebook
  • LinkedIn
  • Twitter
| Print This Article
[-] Text [+]

May 24 (Reuters) - Resverlogix Corp

* Potential of Apabetalone for treatment of high-risk diabetes and CKD is being explored in co's phase 3 Betonmace clinical study

* Says no increase in infections was reported in phase 2 trials

Source text for Eikon:

Further company coverage: